Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Celldex presented positive data from a Phase II study testing the therapeutic cancer vaccine Rintega in patients with EGFRvIII-positive recurrent glioblastoma, including a survival advantage, at ASCO.